Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences deferred income tax expense (benefit) — Foreign ($M) ($M)
Form 10-K Note 15 Income Taxes
Latest, FY2025
-75
Period ended Dec 31, 2025
Change on a year earlier
-170.8%
106 in FY2024
History
12 years
Since FY2014
Sources
9
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Deferred income tax expense (benefit) — Foreign ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -75 | -170.8% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 106 | -371.8% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | -39 | -138.6% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 101 | -314.9% | Form 10-K (filed 2025-02-28) ↗ |
| FY2021 | Dec 31, 2021 | -47 | -223.7% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 38 | -103.1% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | -1,224 | +5,728.6% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | -21 | -135.0% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 60 | -177.9% | Form 10-K (filed 2019-02-26) ↗ |
| FY2016 | Dec 31, 2016 | -77 | +51.0% | Form 10-K (filed 2019-02-26) ↗ |
| FY2015 | Dec 31, 2015 | -51 | +70.0% | Form 10-K (filed 2018-02-27) ↗ |
| FY2014 | Dec 31, 2014 | -30 | – | Form 10-K (filed 2017-02-27) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Deferred income tax expense (benefit) — Foreign ($M) ($M), annual FY2014–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/tax_def_for
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.